Yes several have raised concerns about the Chinese partner, they should address those concerns. It looks like they are trying to crack down, but I'm not sure where they are now.


Jan 2018
https://www.securingindustry.com/pharmaceutic...OVHeY97nIU

Quote:

---

However, the Commission report notes that the current intellectual property landscape in China could be an issue for US pharma firms. Under Chinese law, a company cannot bring a patent infringement case against a patent violator until the violator has launched its product on the market, the report says. “As a result, a US drug company must allow a patent violator to enter the market before it can take action.”

Injunctions to prevent patent abuse during litigation are rarely granted in pharmaceutical cases, while damages awarded by Chinese patent courts are often insufficient to recover lost revenue in the pharmaceutical sector or to prevent infringement, the report adds. Furthermore, there are issues with a large backlog of regulatory approval applications in China, creating a barrier to market access.

The US Department of Commerce case study also highlights broader issues around access to the Chinese market. “IP violations, counterfeit medicines, price controls and a lack of transparency remain some of the most commonly cited barriers to better penetration of the Chinese market,” it says.

---

Oct 2018

http://www.xinhuanet.com/english/2018-10/23/c_137550957.htm

Quote:

---

China considers tougher law against counterfeit drugs

---